GPER1 and cutaneous melanoma: In contrast, the treatment with the GPER agonist G-1 in preclinical studies has consistent antitumor activities in several cancers, including cutaneous melanoma (9), breast (24), ovarian (20, 35), pancreatic (17), and glioma (19).